Johnson & Johnson announced that TREMFYA (guselkumab) maintained or improved fistula remission in adults with Crohn's disease through 48 weeks in the Phase 3 FUZION study. The combined fistula remission rate increased from 28% at Week 24 to 35% at Week 48 for the 100 mg dose group, showing durable benefits in a challenging Crohn's complication. This trial is the first in 20 years to demonstrate efficacy in a randomized, placebo-controlled setting for perianal fistulizing Crohn's disease. The safety profile remained consistent, reinforcing TREMFYA as a promising long-term treatment option for patients with limited alternatives.
Johnson & Johnson's stock trades at USD 253.29 on Pluang as of Oct 19, 2026 19:02 WIB, down 0.89% for the day. This price sits closer to its 52-week high of USD 278.43 than its low of USD 186.00, indicating relatively strong market positioning despite the slight daily dip. The stock's dividend yield of 2.1% adds an income aspect for investors holding it over the typical 130-day period on Pluang.
Johnson & Johnson reported a solid quarter with 6% sales growth and strong oncology business expansion, despite a slight miss in MedTech. Analysts maintain a bullish outlook with a 12-month price target of $291.60, implying a 15.6% upside from curren...
Jim Cramer and financial analysts recommend investors diversify portfolios with stable, dividend-paying stocks like consumer staples, pharmaceuticals, and waste management to protect against tech sector downturns. These 'quiet winners' continue to de...
Johnson & Johnson's recent quarterly report showed its MedTech segment sales fell short of Wall Street expectations, primarily due to pricing pressures in China and budget cuts in Europe. This shortfall caused the company's shares to decline, impacti...
